PACIRA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.25 USD | +0.57% |
|
-2.16% | -22.20% |
Presenter SpeechBalaji Prasad (Analysts)Good morning, everyone. My name is Balaji Prasad. I le...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
26.25
USD
Average target price
45.73
USD
Spread / Average Target
+74.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.20% | 1.21B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Transcript : Pacira BioSciences, Inc. Presents at Barclays Global Healthcare Conference 2022, Mar-16-2022 10
